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Abstract: Functional cognitive disorder (FCD) is a relatively common cause of cognitive symptoms,
characterised by inconsistency between symptoms and observed or self-reported cognitive function-
ing. We aimed to improve the clinical characterisation of FCD, in particular its differentiation from
early neurodegeneration. Two patient cohorts were recruited from a UK-based tertiary cognitive
clinic, diagnosed following clinical assessment, investigation and expert multidisciplinary team
review: FCD, (n = 21), and neurodegenerative Mild Cognitive Impairment (nMCI, n = 17). We
separately recruited a healthy control group (n = 25). All participants completed an assessment
battery including: Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test Part B (TMT-
B); Depression Anxiety and Stress Scale (DASS) and Minnesota Multiphasic Personality Inventory
(MMPI-2RF). In comparison to healthy controls, the FCD and nMCI groups were equally impaired on
trail making, immediate recall, and recognition tasks; had equally elevated mood symptoms; showed
similar aberration on a range of personality measures; and had similar difficulties on inbuilt perfor-
mance validity tests. However, participants with FCD performed significantly better than nMCI on
HVLT-R delayed free recall and retention (regression coefficient −10.34, p = 0.01). Mood, personality
and certain cognitive abilities were similarly altered across nMCI and FCD groups. However, those
with FCD displayed spared delayed recall and retention, in comparison to impaired immediate recall
and recognition. This pattern, which is distinct from that seen in prodromal neurodegeneration, is a
marker of internal inconsistency. Differentiating FCD from nMCI is challenging, and the identification
of positive neuropsychometric features of FCD is an important contribution to this emerging area of
cognitive neurology.
Keywords: functional cognitive disorder; functional neurological disorder; dementia; neurodegener-
ation; neuropsychometry
1. Introduction
A significant proportion of people attending memory clinics have a functional cause
for their cognitive symptoms [1–3]. This may be easily recognised by an experienced
clinician, but in many cases there is ambiguity, leaving the patient in diagnostic limbo
during referral processes, investigations and protracted follow-up. Functional disorders
are characterised by an ability to perform a task well at certain times, but with significantly
impaired ability at other times (such as limb weakness, or difficulty recalling a number
sequence), which often worsens when attention is directed towards the symptoms. This
“internal inconsistency” is persistent over time, and does not simply disappear once
highlighted to the patient [4].
Data on longer-term outcomes for functional cognitive disorders (FCD) is lacking.
A systematic review examining many predominantly memory clinic-based samples with
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cognitive symptoms suggested functional symptoms to be frequent and that the large
majority did not progress to dementia [5]. However, a tertiary memory clinic study found
FCD symptoms generally persisted over 20 months’ follow up [6]. A positive diagnosis
of FCD is important to facilitate development of evidence based treatments (currently
none exist), and also to avoid inappropriate inclusion of people with FCD in studies of
neurodegenerative disease [7].
Key to improving FCD diagnosis is the identification of positive clinical features.
Specific signs of internal inconsistency have been identified in other functional disorders [8].
Markers of cognitive internal inconsistency include: patient recognition that cognitive
performance fluctuates under different circumstances; informant reports of cognitive
ability being more favourable than self-report, or a higher level of concern in the subject
than their informant (the opposite scenario to that seen in people with neurodegeneration);
and performance in clinical interview. For example, providing a fluent, richly illustrated
personal history, and/or informant reports of normal cognition [9], is internally inconsistent
with self-reported enduring severe cognitive symptoms.
Neuropsychometric assessment allows testing of cognitive sub-domains (such as
declarative memory recall versus recognition), in a robust and detailed manner. Deficits
in delayed recall and recognition appear to be particularly good markers of amnesia
displayed in early Alzheimer’s disease [10,11]. Recognition memory has at times been
characterised as indexing familiarity (rather than recollection, which is more closely linked
to recall memory). However, the experimental evidence supporting this can alternatively
and more parsimoniously be interpreted as distinguishing strong memories from weak
memories [12]. Recognition and recall involve overlapping processes located within medial
temporal lobe structures, and therefore we might expect different health conditions to
affect them differentially. Familiarity requires a subject to identify an object, and judgement
that it occurred previously; disorders that affect meta-cognition presumably affect the
judgement process more than the identification process.
Psychological assessments commonly include performance validity tests (PVTs),
which aim to identify feigned symptoms due to conscious, deliberate underperformance.
However, PVTs do not just assess intrinsic motivation: they often require high levels of
effort [13]. Test invalidity may be suspected when “easy” items are failed at a higher rate
than “hard” items, but the superficially “easier” task (e.g., recognition) may involve a
non-completely-overlapping set of cognitive processes compared to the “harder” task (e.g.,
delayed free recall). PVTs are not consistently failed by people with functional disorders,
and the rate of failure appears similar to other clinical conditions such as epilepsy or mild
levels of neurodegeneration [13,14], even when there is a strong motivation for participants
to do well [15]. The use of PVTs in functional disorders is problematic since these disorders
are not caused by conscious deliberate underperformance. However, low scores may
suggest poor “cognitive effort” and should lead to careful consideration of the validity of
the remainder of a cognitive test battery.
Prior research examining personality traits suggests patients with functional neurolog-
ical disorders (including motor symptoms, non-epileptic attacks, fibromyalgia and chronic
fatigue) may exhibit lower levels of extraversion [16], higher neuroticism [17–20], higher
somatisation, [21] and score highly on items targeting symptom over-reporting [22,23].
Many patients with functional disorders do not have personality difficulties [24] and study
results vary depending on the recruitment source, personality model used, and comparator
groups [25]. People with functional disorders affecting other organ systems (such as irrita-
ble bowel syndrome and fibromyalgia) display a similar profile of cognitive difficulties to
one another [13], including difficulties in executive function and selective attention.
The present study examined patterns of mood, cognitive and personality indices
amongst a group with FCD, identified from a tertiary memory clinic. We compared them to
(a) healthy age-matched controls, and (b) a group with neurodegenerative Mild Cognitive
Impairment (nMCI) from the same clinic. This “disease control” group is important in order
to reflect the clinical diagnostic differentiation problem. We hypothesised that the nMCI
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group would have the highest level of cognitive difficulty, and that the FCD group would
have greater mood and personality problems. We were careful to collate a representative
sample of participants, many of whom experience low levels of anxiety and depression, or
may use low levels of medications that can cloud cognitive abilities.
2. Materials and Methods
2.1. Recruitment
Participants with FCD or nMCI were recruited from a tertiary cognitive disorders
clinic, following clinical assessment by a consultant neurologist, appropriate neuroimaging
and neuropsychological assessment. All but one attended at least one follow-up appoint-
ment. Diagnoses were reviewed at a multidisciplinary meeting comprising three cognitive
neurologists, a consultant neuropsychologist and a specialist nurse. Exclusion criteria were:
toxic or metabolic causes of cognitive decline (including current or prior alcohol or sub-
stance abuse, or significant use of potentially psychoactive medication), major psychiatric
disorder, or active systemic disease which could impact on cognition. We purposefully did
not exclude persons with mild mood or anxiety symptoms which (in the opinion of the
cognitive neurology team) were not the major cause of the reported cognitive symptoms.
Patients using low levels of potentially psychoactive medications were included, where
clinicians felt this was unlikely to considerably affect cognition. FCD was diagnosed in
those with a significant discrepancy between severe self-reported cognitive symptoms
and good reported or observed everyday functioning or test performance, no alternative
diagnosis, and no evidence of progressive decline. Those with positive clinical evidence of
neurodegeneration were excluded from the FCD group. A diagnosis of nMCI was made in
participants with evidence of mild impairment on cognitive testing, but with preserved
everyday cognitive functioning, and with clinical evidence of neurodegeneration (e.g., ab-
normal neuroimaging, evidence of a progressive trajectory, or CSF biomarkers, though note
these were not all routinely collected for all study participants). One additional participant
with nMCI was recruited from the Join Dementia Research database, and their diagnosis
was reviewed by a cognitive neurologist (C.P.).
Healthy controls (HC) were recruited from a local database of adult research volunteers
and the Join Dementia Research database. Controls self-identified as having no significant
cognitive complaints. People with current or prior alcohol or substance abuse, significant
use of potentially psychoactive medication, major psychiatric disorder, or active systemic
disease which could impact on cognition were excluded.
The project was given Research Ethics Committee approval by the South West—
Cornwall and Plymouth Research Ethics Committee, REC reference 15/SW/0298 and IRAS
project ID:188539. All participants provided informed consent. The study was funded by
the BRACE charity.
A previous publication on this sample [26] describes that during the course of clinic
follow-up, the likely diagnostic category changed for two participants, and these were not
included in the current analysis (one was re-allocated from nMCI to FCD, and one from
FCD to nMCI).
2.2. Questionnaires
Participants completed locally-devised questionnaires reporting on their household
and employment circumstances, comorbidities and medication use. Comorbidities were
listed, and then used to create binary categories indicating:
• vascular risk factors (hypertension, diabetes mellitus, hypercholesterolaemia, atrial
fibrillation, coronary or cerebral or peripheral vascular disease), or use of medications
unequivocally for these conditions;
• functional conditions excluding FCD (irritable bowel syndrome, non-epileptic attack
disorder, chronic fatigue syndrome/myalgic encephalomyelitis, fibromyalgia);
• depression or anxiety, or use of medications unequivocally for this indication (e.g.,
including SSRIs but excluding amitriptyline and St John’s Wort);
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• medications were listed and screened to identify those that can potentially impair
cognition (this comprised patients on low levels of opiates, tramadol, pregabalin,
gabapentin, lamotrigine, sleeping tablets, or amitriptyline).
2.3. Cognitive and Mood Assessments, and Analysis
Cognitive assessments included the Trail Making Test part B (TMT-B) [27] and the
Hopkins Verbal Learning Test-Revised (HVLT-R) [28]. Participants also completed the
Depression Anxiety and Stress Scales (DASS) [29]. The DASS subscales, and the TMT-B
scores, had skewed residuals (and unequal variances), so were log transformed prior to
linear regression analysis. The HVLT data were very skewed, so age-corrected t-scores
were used in place of the raw data.
In addition to the standard metrics, as a post-hoc analysis examining the HVLT-R word
recognition data, we also calculated D-prime, which is a measure of discrepancy between
subjects’ ability to distinguish signal from noise [30]. To calculate this, raw probabilities of
true hits (H) and false alarms (FA) were generated from the data, then
D prime = z(H) − z(FA) (1)
where z indicates the z-transformation from the probability (note, where probabilities were
exactly 1 or 0 they were adjusted away by 0.01). Due to negative skew, the d-prime scores
were square transformed prior to linear regression analysis.
2.4. Performance Validity, Personality Assessment, and Analysis
The Minnesota Multiphasic Personality Inventory 2 Restructured Form (MMPI-2-
RF) [31] produces a number of embedded PVTs as well as 43 personality “substantive
scales”. The raw responses for each scale were statistically transformed to uniform t-scores.
Using the embedded PVTs, firstly, we looked for participants who consistently gave
a pattern of random or fixed responses (predominantly “true” or predominantly “false”
responses regardless of the question content, termed VRIN or TRIN). We also identified
participants who answered fewer than 90% of the constituent items and “potentially failed”
this scale (those whose item failure rate combined with the unanswered items could have
put them beyond the failure threshold). Where this pattern of potentially random or
fixed responses was found, the remainder of the MMPI-2-RF results for these participants
were excluded.
The remaining PVTs identify over or under reporting of symptoms. Over-reporting
may occur due to feigning or malingering, but high scores are also generated in the context
of multiple somatic symptoms [32]. Therefore, we did not use the remainder of these
PVTs to exclude participants’ data, except where a very extreme score was recorded (i.e.,
an F scale raw score > 30; no participants were excluded at this threshold). A similar
approach has been used elsewhere [17]. The “over-reporting” scales are: F-r (infrequent
reporting), Fp-r (infrequent psychopathology reporting), Fs-r (infrequent somatic report-
ing) and FBS-r (Fake Bad Scale). Under-reporting (i.e., implausibly virtuous behavior or
absence of any bodily symptoms) is measured in scales L-r (uncommon virtues) and K-r
(adjustment validity).
To examine the MMPI-2-RF substantive scales, we ran linear regression models on the
t-scores (which incorporate standardization and controls for age). We excluded individual
substantive scales per participant where >10% of items were blank, “unsure” or otherwise
not codable. We focused on a small number of pre-defined hypotheses based on published
literature [16–19,21,22,24]. We hypothesized that the FCD group, in comparison to nMCI
and HC, would show:
1. higher levels of emotional/internalising dysfunction (“EID”)
2. higher somatic complaints (excluding cognitive complaints) (“RC1”)
3. higher cognitive complaints (“COG”)
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4. fewer positive emotional experiences, and avoid social situations and interactions
(“INTr”)
5. higher scores on scale “NEGE-r” (indicating those prone to experiencing a wide range
of negative emotional experiences, which is associated with neuroticism in the 5-factor
model of personality)
Statistical analysis was undertaken using Stata version 15.1.
3. Results
3.1. Demographics and Background
As previously described [26], participants comprised 21 with FCD, 17 with nMCI
and 25 healthy controls. The FCD group was age matched to healthy controls, but the
nMCI group was significantly older. There were no group differences in sex nor years
of education (Table 1). Rates of employment were 35% in FCD, 6% in nMCI and 48%
in healthy controls (chi2 = 8.3, p = 0.16); note that this is in line with the age difference:
those not employed comprised two off-sick, six unemployed and 36 retired. There was
no difference in the proportion of participants who live with relatives (85% for FCD, 82%
for nMCI and 80% for healthy controls) versus living alone (chi2 = 0.19, p = 0.91). The
percentages reporting being a carer did not differ across groups (25% for FCD, 25% for
nMCI and 12% for healthy controls, chi2 = 1.58, p = 0.45).
Table 1. Demographics, comorbidities and current medication use per group.
FCD Healthy nMCI
Mean (SD) ANOVA F (p)
Age 58.3 (12.6) 60.8 (5.8) 72.1 (11.7) 9.59 (<0.01)
Years of education 13.8 (2.8) 14.7 (3.7) 14.4 (3.0) 0.50 (0.61)
n (%) per group Chi2 (p)
Sex (female) 10 (48) 18 (72) 8 (47) 3.73 (0.15)
Vascular risk factors 8 (40) 7 (28) 14 (82) 12.55 (<0.01)
Other functional disorder
(excluding FCD) 4 ˆ (20) 4 ˆˆ (16) 0 (0) 3.63 (0.16)
Depression or anxiety 5 (24) 3 (12) 3 (18) 1.19 (0.55)
Medication with potential
cognitive side effects 9 (43) 8 (32) 5 (29) 1.20 (0.55)
ˆ 2xfibromyalgia, 1xChronic Fatigue/Myalgic Encephalomyelitis, 1xNon-Epileptic Attack Disorder. ˆˆ 2xfibromyal-
gia, 1xChronic Fatigue/Myalgic Encephalomyelitis, 1xIrritable Bowel Syndrome.
Comorbidity and medication data are listed in Table 1. The only statistical difference
found was in the level of vascular comorbidity, which was higher amongst the nMCI group
(82% had at least one vascular risk factor, compared to 40% in the FCD group and 28% in
the healthy controls). This is expected since the nMCI group have a neurodegenerative
diagnosis (including cases of vascular MCI), and also higher average age. There was no
group difference in the level of other functional disorders (excluding FCD), depression or
anxiety, or use of psychoactive medication, but sample sizes are small for binary outcome
comparisons. A history of structural brain lesions was uncommon but not absent (FCD:
one head injury, one stroke; nMCI: one brain tumour, one stroke; healthy controls: one
subarachnoid haemorrhage).
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3.2. Depression, Anxiety and Stress
Depression, anxiety, and stress levels were each similar across FCD and nMCI groups,
but this represented an elevation compared to healthy controls (Table 2).
Table 2. Depression Anxiety and Stress Scale (DASS) per group.
Depression Anxiety and Stress Scale Mean (SD) Regression 1: Coefficient (p)
FCD Healthy nMCI FCD vs. Healthy FCD vs. nMCI
Depression 11.1 (11.4) 3.4 (4.8) 8.6 (8.3) −1.13 (<0.01) −0.38 (0.30)
Anxiety 9.9 (10.5) 3.1 (4.3) 8 (6.7) −1.11 (<0.01) −0.14 (0.71)
Stress 12.2 (9.9) 5.2 (5.1) 11 (8.0) −0.88 (<0.01) −0.0.17 (0.62)
1 DASS subscales have been log-transformed prior to regression. Regression models control for age and sex.
3.3. Cognitive Testing
The raw scores on TMT-B showed those with FCD scoring intermediately between
healthy controls and those with nMCI (Table 3). However, this difference disappeared
following correction for age in the regression analysis: participants with FCD scored higher
(worse) than healthy controls, but no differently to nMCI.
Table 3. Cognitive testing (TMT-B and HVLT-R).
Scale Regression: Coefficient (p)
FCD H nMCI FCD vs. H FCD vs. nMCI
TMT-B 1 Mean (SD)
Time in seconds 105 (74) 75 (38) 134 (82) −0.40 (0.02) −0.02 (0.92)
HVLT-R 2 Raw score mean; t-score mean (SD)
Total recall (trials 1-3) 20.9; 37.3 (12.3) 24.4; 45.7 (10.6) 16.1; 33.7 (8.8) 9.13 (<0.01) −3.60 (0.31)
Trial 4 recall (delayed recall) 7.4; 40.3 (14.0) 9.5; 49.2 (10.0) 3.8; 31.8 (10.1) 8.86 (0.02) −8.52 (0.03)
Retention (trial 4/best of trial 2 and
trial 3) 0.79; 43.1 (14.1) 0.92; 50.0 (9.9) 0.48; 32.8 (12.1) 6.99 (0.07) −10.34 (0.01)
Recognition discrimination index
(recognition hits minus false positives) 7.2; 36.4 (14.0) 10.8; 50.5 (8.3) 7.6; 34.9 (11.5) 14.12 (<0.01) −1.45 (0.71)
Mean (SD)
D-prime 1 2.22 (1.58) 3.68 (0.84) 2.18 (1.12) 12.62 (<0.01) −0.30 (0.94)
1 TMT-B and D-prime scores were transformed prior to regression. Regression model also controls for age and sex. 2 HVLT-R scales
(excepting D’) used T-scores incorporating normalisation and age-correction; regression models controlled for sex.
HVLT-R scores for immediate free recall (trials 1–3) were equally impaired in FCD
and nMCI groups compared to healthy controls. The same was found for recognition
discrimination index (recognition hits minus false positives, and similarly if this was
calculated as “D-prime” to better distinguish signal from noise on recognition ability).
However, the trial 4 free recall (after a delay of 20 min), and similarly the retention score
(trial 4 free recall divided by the best score of trials 2 or 3), showed that participants with
FCD scored significantly better than those with nMCI (trial 4 recall 40.3 vs. 31.8, t-2.0, p0.03;
retention 43.1 vs. 32.8, t-2.56, p = 0.01) (see also Figure 1).
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Figure 1. HVLT-R t-scores, demonstrating the discriminability of FCD from nMCI and Healthy Control groups, on measures
of Immediate Recall, Delayed Recall, and Recognition.
3.4. Personality Data
3.4.1. Embedded Performance Validity Measures
First we calculated how many individual items were unscorable (“don’t know”,
marked ambiguously, or left blank). We examined how many returned at least 15/338
items unscorable, and those who returned more than one scale unusable because >90% of
items in that scale were unscorable (Table 4). The rates were elevated in FCD and nMCI
compared to healthy controls (in fact the percentage with high levels of unscorable items
was greater in nMCI, 60%, than in FCD, 25%, chi2 = 2.2 p = 0.04). Next, we identified those
who failed or potentially failed the test of fixed or random responding (comprising two
FCD participants, four nMCI participants, and no healthy controls). These participants
were excluded from further analysis of the MMPI measures.
Both FCD and nMCI groups (compared to healthy controls) scored relatively high
on “over-reporting” (this was significantly higher in FCD than healthy controls, p < 0.01,
but not statistically higher in FCD compared to nMCI, p = 0.73). No participant showed
significant elevation on scales assessing “under-reporting” of symptoms. Note that we
did not exclude data from personality content analysis on the basis of a high rate of
unscorable items or over-reporting, unless >10% of items from the scale under examination
were unscorable.
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Table 4. Minnesota Multiphasic Personality Inventory (MMPI-2-RF)—validity tests and content scores per group.
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1 Out of 338 items in MMPI-2-RF. “Unscorable” means left blank, or marked “cannot say” or marked both true and false for one item.
2 Out of 50 scales. 3 Random responding (VRIN) indicates variable-inconsistent responses to items of consistent content. Fixed responding
(TRIN) indicates fixed True or False responses regardless of items content. 4 Over-reporting scales comprised: F-r (infrequent reporting),
Fp-r (infrequent psychopathology reporting), Fs-r (infrequent somatic reporting) and FBS-r (Fake Bad Scale). 5 Individual scales were
excluded from further analysis if either the individual scale had >10% unscorable items; or the participant had potentially random or fixed
reporting. EID = Emotional/Internalising Dysfunction; RC1 = Somatic complaints (note this does not include any cognitive complaints);
COG = cognitive complaints; INTRr = a scale denoting “fewer positive emotional experiences, and avoidance of social situations and
interactions”; NEGEr = a scale denoting being “prone to experiencing a wide range of negative emotional experiences”, this is associated
with Neuroticism in the 5-factor model of personality.
3.4.2. Personality Content
This analysis focused on testing 5 pre-defined hypotheses. Patients with FCD scored
higher than healthy controls on each of the following scales: EID, RC1, COG and NEGEr.
There was no group difference in INTr. However, the FCD group was not significantly
different to the nMCI group on any of these indices.
We have also listed the mean and standard errors for each of the substantive scales
as an appendix (Supplementary Table S1), as this type of personality profile has not been
previously published for FCD patients.
4. Discussion
This clinic-based comparison of neuropsychological patterns aimed to identify novel
markers of FCD. The most striking finding was the similarity between FCD and nMCI
groups, in terms of memory performance, levels of depression or anxiety symptoms, and
personality traits. Secondly, we found a psychometric pattern suggesting cognitive internal
inconsistency in those with FCD. Thirdly, both the FCD and nMCI groups showed a similar
rate of sub-optimal performance validity on embedded indices built into the personality
assessment. This highlights the importance of carefully considering what “performance
validity” really indexes in these populations. The nMCI group were significantly older than
those with FCD. Although age alone cannot be used reliably to differentiate neurodegenera-
tive from functional problems in the clinic, older age makes neurodegeneration more likely,
so clinicians may be more comfortable making a functional diagnosis in younger patients.
We found a cognitive profile that (if replicated) could be used in positive diagnosis of
FCD. People with FCD struggled with immediate recall and recognition tasks, as did those
with nMCI, but people with FCD performed surprisingly well on delayed recall. Encoding
by FCD participants presumably operated at a reasonable level in order to support their
delayed recall, but counter-intuitively, their encoding ability did not translate into results
on either the immediate recall or recognition tasks.
One explanation for this cognitive profile follows from the ideas of Yerkes–Dodson
“law” (in which increasing arousal, in light of increasing task difficulty, improves task
performance but only up to a certain limit, after which performance decreases). Potentially,
the delayed recall task matches the FCD group’s preferred optimal level of task difficulty.
However, this group elsewhere struggled with other “hard” tasks, such as the National
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Adult Reading Task (often used as an index of pre-morbid intelligence) [26]. Alongside
this difficulty-performance curve, there is also a (small but robust) association between
memory performance and memory self-efficacy in healthy people, and such associations
are stronger in more attention-demanding tasks (a stronger association when examining
delayed recall rather than recognition tasks) [33]. It is plausible that the task that is most
cognitively demanding may differ between healthy people and those with FCD or those
who are prone to introspection.
An alternative explanation involves the greater requirement for introspection on
recognition versus recall tasks (such as incorporation of priors and other metacognitive
processes thought to be involved in the generation of internal inconsistency) [34]. A related
component contributing to arousal in FCD is likely to be the participant’s perception of
their poor performance relative to others. These perceptions may be less tangible during
the delayed recall task than in the immediate recall or recognition tasks, which participants
might expect healthy people to be able to complete easily. If this were true, then more
generally FCD participants should perform well on tasks that rely on implicit memory, but
less well on conscious and explicit memory. Better-than-expected performance on delayed
recall than immediate recall can sometimes be related to a heavy cognitive or attentional
load [35]. This extra cognitive load may be due to a switch from a more automatic to a
more explicit mode of processing, as is hypothesised to occur in patients with FCD [13].
It is also important to consider parallels to cognitive impairment in depressed groups,
in whom subjective reports of cognitive underperformance and heightened cognitive
effort, apparently outweigh objective performance. Although such groups often do not
have an objective cognitive score in the impaired range, intra-individual comparisons
revealed reductions in performance compared to pre-morbid estimates [36]. Therefore,
subjective experience of heightened cognitive effort compared to pre-morbid experiences
likely contributes to lack of cognitive confidence, which also “may raise disproportional
negative beliefs about one’s ability to function in day-to-day activities.”
Previous studies have shown patients with early Alzheimer’s disease perform poorly
on both delayed recall and recognition [10,11]. People with feigned cognitive disorders
compared to credible cognitive complainants tested using HVLT-R also showed a different
pattern: worse performance in each of delayed recall, retention and recognition [37] and
similar results have been found when using the related RAVLT instrument [38,39]. One
study has reported RAVLT cognitive patterns in depressive pseudodementia (compared to
healthy controls), which showed low scores on almost all subcomponents, with the excep-
tion of preserved recognition memory [40]. These findings suggest there are qualitatively
different cognitive lapses occurring in participants with FCD, compared to those operating
in early neurodegeneration, feigned symptoms, or depression. Caveats to directly compar-
ing these studies include small sample sizes, differing control comparison groups and the
mix of different instruments used.
Our personality data firstly allowed scrutiny of the use of embedded symptom validity
testing. “Failing” this did not discriminate between functional cognitive problems and
difficulties experienced in early neurodegeneration. Secondly, the substantive personality
scales were also notable for similarity across these two groups: features linked to inter-
nalising problems, somatic complaints and neuroticism were all higher in patients with
FCD and those with early neurodegeneration, relative to healthy controls. This raises the
possibility that personality differences, as well as scores on self-reporting of mood scales,
could be an outcome of cognitive symptoms, whatever their root aetiology.
Important limitations to our study include firstly the small sample size, which limits
the robustness of statistical analyses, and may have hindered our ability to detect small
between-group differences. For this reason, we curtailed covariates in regression models
such that we controlled only for age and sex, and we ran limited analyses on the personality
data (testing pre-defined hypotheses as suggested by prior literature). Secondly, the
participants have not undergone long-term follow up. However, almost all the FCD and
nMCI participants had at least two clinic visits (this resulted in raised diagnostic uncertainty
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in one participant each of those originally assigned to FCD and nMCI groups, who were
excluded for the analyses reported here [26]). Thirdly, the nMCI group was intended to
represent a representative clinic sample, with a range of underlying diagnoses (including
Alzheimer’s disease and vascular cognitive impairment). Therefore, inclusion in this
group was based on consensus clinical opinion, and investigations relevant to their clinical
management, rather than a blanket battery of investigations. Fourthly, the cross-sectional
nature of this study means that we cannot make inferences about the causal relationship
between any of mood, personality or cognitive patterns, and diagnostic group.
5. Conclusions
Overall, this study has highlighted similarities on measures of mood, personality
and superficial cognitive testing, amongst those with mild cognitive impairments due to
functional and neurodegenerative causes. However, detailed analysis of cognitive profiles
demonstrated positive evidence of cognitive internal inconsistency in the FCD group.
This supports efforts to refine the diagnosis of FCD, away from simply an exclusion of
relevant differential diagnoses, towards the detection of positive clinical findings, including
neuropsychometric evidence of internal inconsistency.
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